FGF1, FGF15/19, FGF21, and their targets provide interesting therapeutic possibilities for the treatment of metabolic diseases, such as obesity, non-alcoholic fatty liver disease, type 2 diabetes, and atherosclerosis (3, 4, 17). Here, FGF21 is linked to obesity due to melanocortin 4 receptor deficiency.